IsoRay Continues to Support Innovative Techniques in Brain Cancer Treatment
RICHLAND, Wash., May 30, 2018 (GLOBE NEWSWIRE) — IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not-for-profit health system based in Louisiana.
The funding is intended to support a study entitled “Comparison of Minimally Invasive Keyhole Craniotomy and Stereotactic Radiosurgery for the Treatment of New Brain Oligometastases: A Prospective, Open Label Study”. The study will be led by Dr. Marcus Ware M.D., Ph.D., Medical Director of Neurosurgical Oncology at Ochsner. Dr. Ware is a Harvard Medical School graduate who completed his residency at the University of California, San Francisco, one of the premiere programs in the world in brain tumor surgery and neuro-oncology. At Ochsner, he specializes in the treatment of primary and metastatic brain tumors.
Dr. Ware has actively pursued therapies that effectively address various brain cancers while minimizing impact on quality-of-life throughout his career. This new study will explore IsoRay’s signature Cesium-131 therapy seed placed at the time of a brain surgery, a technique known as “keyhole” surgery. The combination of this minimally invasive surgery with Isoray’s highly conformal radiation therapy is intended to provide definitive treatment of brain tumors with surgery and radiation with as little impact on a patient’s quality of life as possible.
Bill Cavanagh, Chief Scientific Officer of IsoRay commented, “We are pleased to work with Dr. Ware, an accomplished expert, and look forward to working with an organization with a reputation of the caliber of Ochsner. We believe that evidence is being compiled that could demonstrate the advantages of Isoray’s Cesium-131 brachytherapy at the time of brain tumor resection over other conventional approaches.”
“This new study by Dr. Ware adds to the growing list of distinguished physicians and institutions, including Weill Cornell and the Barrows Neurological Institute, who have recognized the positive results that can be achieved with Cesium-131 on brain cancer, a large unmet medical need,” added Tom LaVoy, CEO of IsoRay.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.
Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of Cesium-131 and its delivery systems, whether interest in and use of our products for brain treatments will increase or continue, the evidence which may demonstrate the advantages of our brain tumor resection over other conventional approaches, continued positive industry data fueling renewed interest in brachytherapy and Cesium-131 for brain treatments, strong patient results, the perception by patients of quality of life outcomes, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether the evidence demonstrates our brain tumor resections are more favorable over conventional approaches, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, changes in laws and regulations applicable to our products, the use of competitors’ products in lieu of our products, and other risks detailed from time to time in IsoRay’s reports filed with the U.S. Securities Exchange Commission. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: IsoRay, Inc. email@example.com (509) 375-1202 Investors: Stephanie Prince, Managing Director PCG Advisory Group firstname.lastname@example.org (646) 762-4518